MagnetisMM-32 is a Phase 3, open-label study of elranatamab monotherapy versus investigator’s choice of elotuzumab, pomalidomide & dexamethasone (EPd) or pomalidomide, bortezomib & dexamethasone (PVd) or carfilzomib & dexamethasone (Kd) in participants with relapsed/refractory multiple myeloma (RRMM) who received prior anti-CD38 directed therapy.
MagnetisMM-32 will investigate whether elranatamab monotherapy (Arm A) can provide superior clinical benefit compared to investigator’s choice (Arm B, EPd or PVd or Kd) in participants with RRMM who have received at least 1 prior line of therapy but no more than 4 including lenalidomide and anti-CD38-targeting therapies.
BCMA
B-cell maturation antigen (BCMA) is a particularly promising target for cell-directed therapy as this protein is uniquely found on the surface of plasma cells and is nearly non-existent on surrounding naïve and memory B cells.
Additionally, BCMA overexpression on plasma cells and BCMA activation are associated with the progression of multiple myeloma, creating a useful biomarker for this investigational targeted therapy.
Click below to view a video on BCMA as a target for multiple myeloma treatment
Elranatamab
Elranatamab, the investigational therapy from Pfizer that is being assessed in the MagnetisMM-32 study, is administered as a subcutaneous injection.
Elranatamab binds to both BCMA proteins on cancerous plasma cells and to CD3 receptors on the surface of a patient’s own T-cells.
The investigational therapy then bridges these cells together with the ultimate goal of activating an immune response to kill the cancer cells.
Is MagnetisMM-32 right for my patient?
MagnetisMM-32 is enrolling adult patients (18+) who:
Have multiple myeloma and previously received at least 1 but not more than 4 prior lines of therapy for multiple myeloma including:
- At least 2 consecutive cycles of an anti-CD38 antibody-containing regimen in any prior line
AND - At least 2 consecutive cycles of a lenalidomide-containing regimen in any prior line
Documented evidence of progressive disease or failure to achieve a response to last line of multiple myeloma therapy
Have not had previous treatment with a BCMA-directed therapy
Study Design
Approximately 492 participants will be randomly assigned on a 1:1 basis to:
Arm A:
Elranatamab monotherapy
Arm B:
Investigator’s choice of elotuzumab, pomalidomide & dexamethasone (EPd) or pomalidomide, bortezomib & dexamethasone (PVd) or carfilzomib & dexamethasone (Kd)
Participants will receive treatment until confirmed disease progression, unacceptable toxicity, withdrawal, loss to follow-up, or study termination. The length of participation in MagnetisMM-32 will vary depending on how well participants tolerate the study treatment or time to disease progression.
The total time a participant may spend in this trial is approximately 5 years, but this will vary by participant. Participants will visit the study site 1 to 6 times per month during the treatment period of the study.
The study includes a 28-day screening period, the treatment period, and a 28-day safety follow-up.
Long-term follow-up will consist of visits every 1 to 3 months from the last dose until the study is complete, which may take many years, or until the participant withdraws consent.
Connect with a Pfizer Field Medical Director about the MagnetisMM-32 clinical trial
Together we can make a difference
People are often introduced to the world of clinical trials through conversations with their healthcare provider. As with anything new, there may be a number of questions, concerns, or misconceptions. Being their trusted healthcare provider, we appreciate you taking the time to have an open discussion with patients and their loved ones who may be interested in contributing to research.
Clinical trials may serve as valuable treatment options for your patients. While no benefit is guaranteed from an investigational medicine, your patients who participate in a clinical trial will contribute to the process of developing a potential new therapy, and receive regular medical assessments and support throughout their study participation.
If you would like more study-specific information to help inform conversations with potential participants, click here to connect with a Pfizer Field Medical Director. Should any of your patients take part in the MagnetisMM-32 clinical trial, rest assured that they will remain under your medical care for all non-study-related needs and will continue to receive any benefits to which they are entitled. Pfizer gives clinical trial participants the option to access certain individual data, approximately 12 months after study completion. This allows participants to share data with their healthcare provider after their study participation concludes. Participants can register at www.pfizerclinicaltrialalumni.com where they will have access to news, resources, and study results as soon as they become available.